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Because MYC plays a causal role in many human
cancers, including those with hypoxic and nutrient-
poor tumor microenvironments, we have determined
the metabolic responses of a MYC-inducible human
Burkitt lymphoma model P493 cell line to aerobic
and hypoxic conditions, and to glucose deprivation,
using stable isotope-resolved metabolomics. Using
[U-13C]-glucose as the tracer, both glucose con-
sumption and lactate production were increased by
MYC expression and hypoxia. Using [U-13C,15N]-
glutamine as the tracer, glutamine import andmetab-
olism through the TCA cycle persisted under hyp-
oxia, and glutamine contributed significantly to
citrate carbons. Under glucose deprivation, gluta-
mine-derived fumarate, malate, and citrate were
significantly increased. Their 13C-labeling patterns
demonstrate an alternative energy-generating gluta-
minolysis pathway involving a glucose-independent
TCA cycle. The essential role of glutamine metabo-
lism in cell survival and proliferation under hypoxia
and glucose deficiency makes them susceptible to
the glutaminase inhibitor BPTES and hence could
be targeted for cancer therapy.
INTRODUCTION
Mutations of genes involved in the tricarboxylic acid (TCA) cycle,
such as fumarate hydratase, succinate dehydrogenase, or isoci-110 Cell Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Intrate dehydrogenase 1 or 2, are causally linked to familial cancer
syndromes (Bensaad et al., 2006) or spontaneous low-grade
gliomas and acute myelogenous leukemia (Dang et al., 2010).
Together with the well-known Warburg effect (Koppenol et al.,
2011; Vander Heiden et al., 2009; Warburg, 1956; Warburg
et al., 1924) and numerous other alterations in the central metab-
olism of cancers (King et al., 2006; Samudio et al., 2009), these all
point to the important role of metabolism in the development of
many cancers and its therapeutic opportunities (Vander Heiden,
2011). Further, tumor suppressors such as p53 and oncogenes
such as MYC and RAS have been directly linked to regulating
metabolic pathways (Dang et al., 2009a; Telang et al., 2007) for
initiating tumorigenesis and tumor progression. These genetic
changes correlate with an increase in glucose consumption
and lactate production whenMYC is high. However, solid tumors
contain regions that are both hypoxic and glucose depleted
(Schroeder et al., 2005), requiring alternative strategies for sur-
vival and/or proliferation.
Here, we report stable isotope-resolved metabolomic (SIRM)
studies of MYC-induced alterations in glucose and glutamine
metabolism, in which we find persistent, MYC-dependent hyp-
oxic metabolism of glutamine, even in the absence of glucose.
Using NMR andMS, we have traced the fates of individual atoms
from uniformly 13C-labeled glucose ([U-13C]-Glc) or 13C,15N-
labeled glutamine ([U-13C,15N]-Gln) in human B cell P493 cells
carrying an inducibleMYC vector. Overexpressed MYC resulted
in the concurrent conversion of glucose to lactate and the oxida-
tion of glutamine via the TCA cycle. Under hypoxic conditions
with high MYC, a substantial fraction of the glucose consumed
was converted to excreted lactate, and glutamine continued to
be utilized by the TCA cycle, which was used for cell survival.
We further document the finding of a fully 13C-labeled citrate
isotopologue that contained carbons deriving completely fromc.
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Glucose-Independent Glutamine-Dependent TCA Cyclelabeled glutamine, suggesting the existence of a glucose-inde-
pendent TCA cycle. We also found under glucose-depleted
culture conditions that a glutamine-dependent and glucose-
independent TCA cycle may operate under both aerobic and
hypoxic conditions. Moreover, we observed an enhanced con-
version of glutamine to glutathione under hypoxia; glutathione
is an important reducing agent for controlling the accumulation
of mitochondrial reduced oxygen species (ROS). Under mod-
erate hypoxia, excess ROS is generated at complex II owing to
a mismatch between NADH production and terminal oxidase
activity (Wu et al., 2007). We therefore tested whether inhibition
of glutamine metabolism could induce oxidative stress under
hypoxia. We found that inhibition of glutaminase (GLS) by the
glutaminase-selective inhibitor BPTES (Robinson et al., 2007)
elevated ROS levels and diminished ATP levels in hypoxic cells.
In fact, we found that inhibition of glutaminase effectively kills
hypoxic cancer cells in vitro and delays tumor xenograft growth
in vivo.
RESULTS
Coexistence of Oxidative and Aerobic Glycolysis
Our genomic analysis of MYC target genes indicates that
the expression of genes involved in glycolysis and in mito-
chondrial respiration is coregulated by MYC (Dang, 2010; Kim
et al., 2007, 2008; Li et al., 2005). We thus determined the
metabolic consequences of MYC activation in a model cell line
(P493) of human Burkitt lymphoma grown in uniformly labeled
[U-13C]-Glc under aerobic (21% O2) or hypoxic (1% O2) con-
ditions. Although the levels of metabolites at steady state are
the result of the balance between production and consumption,
the use of SIRM enabled us to determine not only steady levels of
metabolites but also the isotopomer and isotopologue distribu-
tions of metabolites derived from 13C-labeled glucose for recon-
struction of metabolic pathways. Time course isotopomer data
on extracellular metabolites further provided flux measurement
for substrate import and product release (Figure 1A, see Fig-
ures S2C and S3B and Table S1 available online). P493 cells
contain a tetracycline-repressible MYC construct, such that
tetracycline withdrawal results in rapid induction of MYC and
tetracycline treatment results in MYC suppression (Figure S1A).
Induction of MYC resulted in an increase of 13C-glucose con-
sumption and 13C-lactate production, which were further accen-
tuated by hypoxia (Figure 1A). NMR analysis of 13C-labeled
metabolites derived from [U-13C]-Glc in cell extracts also corrob-
orated the finding that overexpressed MYC resulted in lactic
fermentation even under aerobic conditions (Figure 1B). The
same cell extracts were further analyzed by GC-MS to quantify
glucose-derived 13C isotopologues of lactate (lactate with dif-
ferent number of 13C atoms) (Figure 1D). Levels of the m+3 iso-
topologue of lactate (triply 13C-labeled lactate or 13C3-lactate)
derived from glucose shown with MYC ON or OFF in aerobic
(A) or hypoxic (H) conditions (Figure 1D) also support the ability
ofMYC to increase aerobic glycolysis (Figure 1C). Under hypoxic
conditions, glucose-derived lactate was increased but was
less dependent on MYC. The production of lactate (Table S1)
accounts for only part of the glucose consumed. Although
a complete carbon inventory has not been achieved, we esti-
mate that a significant fraction of the glucose enters newCellbiomass, which with respiration is associated with carbon loss
as CO2.
As shown in Figure 2, glucose-derived TCA cycle intermedi-
ates under aerobic condition displayed a dependence on
MYC, such that the doubly 13C-labeled isotopologue of citrate
(13C2-citrate), succinate, fumarate, and malate (m+2 forms,
circled red) increased when MYC was ON. Glucose-derived
a-ketoglutarate (m+2), which was at very low cellular concentra-
tion, also demonstrated a dependence on MYC; it was only
detectable when MYC was ON. Hypoxia decreased the MYC-
induced conversion of glucose to citrate (m+2) and to other
m+2 isotopologues of TCA cycle intermediates (malate, fuma-
rate, and succinate), but these activities were independent of
MYC expression (MYC ON-H versus MYC OFF-H). In addition
to the synthesis of 13C2-citrate, there was a significant produc-
tion of 13C5-citrate (m+5, circled green) with MYC ON under
aerobic conditions. This citrate isotopologue could be produced
from m+2 acetyl-CoA plus m+3 oxaloacetate (product of pyru-
vate carboxylation, green arrow and circles, Figure 2) (Fan
et al., 2010), and its level appeared to be attenuated by hypoxia
and the absence of ectopicMYC (Tet treatment). It is notable that
a large fraction (up to 70%) of these TCAmetabolites (m+0) were
not derived from the labeled glucose, suggesting an alternative
source and/or prolonged half-lives of these metabolites that
could have existed prior to the administration of labeled glucose.
Persistence of Glutamine Oxidation via the TCA Cycle
under Hypoxia
The attenuation of glucose entry into the TCA cycle under
hypoxia (Figure 2) is consistent with the hypoxia inducible factor
(HIF)-mediated diversion of pyruvate to lactate (away from
acetyl-CoA) through the induction of LDHA (which increases
the relative flux from pyruvate to lactate) and PDK1 (which
decreases the relative flux from pyruvate to acetyl-CoA) (Kim
et al., 2006). Because it was previously documented that MYC
induces glutamine metabolism under aerobic conditions (Gao
et al., 2009; Wise et al., 2008), we sought to determine whether
glutamine entry into the TCA cycle would also be compromised
by hypoxia.
Using [U-13C,15N]-Gln (13C5
15N2-Gln) as the tracer with SIRM
analysis, the fates of glutamine as a function of MYC induction
and oxygen availability were determined (Figures 3B–3D). Gluta-
mine is transported into cells by transporters, such as the direct
targets of MYC SLC1A5 or ASCT2 (Figure S1C), and then con-
verted to glutamate by glutaminase (GLS, kidney isoform, which
is also a target of MYC) (Figure S1D). 13C5
15N2-Gln (m+7) is con-
verted by glutaminase into 13C5
15N-Glu (m+6) plus 15NH4
+
(Figure 3A). NMR studies of biological replicate experiments
revealed a MYC-dependent conversion of labeled glutamine to
glutamate, which unexpectedly persisted in hypoxia (Figure 3B).
This result was corroborated by the GC-MS analysis of the same
set of polar extracts. Intracellular glutamine was converted to
glutamate (m+6 isotopologue or 13C5
15N1-Glu, Figure 3D) in a
MYC-dependent fashion that persisted under hypoxia. A large
fraction of the m+5 glutamate isotopologue was also present
and displayed a similar MYC and hypoxia dependence as
the m+6 isotopologue. The m+5 isotopologue of glutamate
was largely 13C5-Glu as determined by high-resolution FT-
ICR-MS (Figure S1E), which resolved the neutron mass fromMetabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inc. 111
Figure 1. MYC Induces Aerobic Glycolysis that Is Heightened in Hypoxia
(A) Time course of glucose consumption and lactate secretion into the medium. P493 cells were treated with 0.1 mg/ml tetracycline (MYC OFF) or without
tetracycline (MYC ON) for 48 hr in hypoxic (H) or aerobic (A) conditions and were grown in RPMI containing 10 mM [U-13C] glucose (13C-Glc6) for 24 hr. Media
metabolites and 13C enrichments were measured by 1D 1H NMR. The metabolite amounts are expressed as mmole. Each time data point is an average of
duplicate samples. The rates were calculated from linear regression of the time courses and normalized to cell mass as mmole/h/g cells. Open symbols are
13C lactate, filled symbols are 13C glucose. Filled red circles, MYC ON aerobic; blue diamonds, MYC OFF aerobic; green squares, MYC ON hypoxic; black
triangles, MYC OFF hypoxic.
(B) 1-D 1H{13C} HSQC NMR spectra of cell extracts of P493 MYC ON versus MYC OFF. Intracellular 13C-lactate synthesized from 13C glucose was attenuated
when MYC is off, which was also observed by GC-MS analysis of the same extracts (D). NMR spectra were recorded at 800 MHz and 20C. Each 1H peak arose
from protons directly attached to 13C, and the peak assignment denotes the 13C-carbon. Thus, the peak intensity reflects 13C abundance of the attached carbon.
(C) Diagram of 13C-labeling patterns of glycolytic products with 13C6-Glc as tracer. Glucose with carbons (red circles) labeled at all six positions (blue) generates
13C3-lactate via pyruvate (three carbons), which also produces
13C2-acetyl CoA.
(D) GC-MS analysis of MYC and/or hypoxia effect on 13C-Glc6 metabolism to different
13C isotopologues of lactate. Overexpressed MYC enhanced lactate
production (most notably 13C3-lactate; m+3), and hypoxia further increased labeled incorporation into lactate. Each value is an average of duplicate samples. The
error bars represent SEM.
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Glucose-Independent Glutamine-Dependent TCA Cycle13C and 15N. 13C5-Glu should be a transamination product of
13C-labeled glutamine-derived a-ketoglutarate (a-KG) with unla-
beled nitrogen sources (Figure 3A). a-ketoglutarate levels also
tracked MYC expression (Figure 4). Furthermore, the depen-
dence of glutaminase activity on MYC expression measured in
extracts suggests that the intracellular conversion of labeled
glutamine to glutamate is at least partly regulated by GLS1
activity in response to MYC (Figure S2A). This was further sup-
ported by the higher level of ammonium ions—the other product
of the glutaminase reaction—that were released into themedium
under MYC ON conditions (Figure S2B).
Levels of fully labeled glutamine in the media were mea-
sured to determine the rate of consumption of glutamine. Gluta-
mine consumption rates were in the following order: MYC ON
aerobic zMYC ON hypoxic > MYC OFF hypoxic > MYC OFF
aerobic (Figure 3C, Figure S2C). The m+5 and m+6 isotopo-
logues of glutamate were also present in themedium (Figure 3C),112 Cell Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inwhich reflects exchange of intracellular glutamine-derived gluta-
mate for other amino acids such as cystine (see below).
As depicted in Figure 3A, labeled glutamine catabolism by
glutaminase led to the production of 13C5-aKG, which can enter
the TCA cycle for further oxidation. As shown in Figure 4, the syn-
thesis of 13C4-succinate, -fumarate, and -malate (m+4) is consis-
tent with the oxidation of 13C5-aKG via the forward reactions of
the TCA cycle (red circles, Figure S2D). These labeled TCA inter-
mediates all responded to MYC status by increasing 60%
to >100% when MYC was ON, regardless of O2 availability (Fig-
ure 4). The levels of 13C4-citrate, which is synthesized in the
second turn from 13C4-oxaloacetate (OAA, derived from labeled
glutamine in the first turn) and acetyl-CoA (from unlabeled glu-
cose or other unlabeled sources) by citrate synthase (CS), also
responded to MYC expression under both aerobic and hypoxic
conditions (Figure 4). These results show that MYC can drive
glutaminemetabolismaround the TCAcycle even under hypoxia.c.
Figure 2. Glucose Entry into the TCA Cycle Is Induced by MYC and Suppressed by Hypoxia
The cycle reactions are depicted without or with pyruvate carboxylation (green arrow), and the 13C isotopomer patterns are the result of one cycle turn. The
isotopologue distributions were determined by GC-MS. The incorporation of 13C atoms from 13C6-Glc into citrate, a-ketoglutarate (a-KG), succinate, fumarate,
and malate are denoted as m+n, where n is the number of 13C atoms. The m+5 (13C5)-citrate (green circle) is produced by condensation of m+2 acetyl-CoA with
m+3OAA (from pyruvate carboxylation), while m+2 (13C2)-citrate is synthesized without input of pyruvate carboxylation. Red and green circles,
13C atoms derived
from 13C6-Glc without or with pyruvate carboxylation, respectively. GPT2, glutamate-pyruvate transaminase; PC, pyruvate carboxylase; CO2 indicates where
carbon dioxide is released. A, aerobic; H, hypoxic. The error bars represent SEM.
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for Survival and Proliferation
In addition to the production of the 13C4-citrate isotopologue,
there was a significant formation of other citrate isotopologues,
e.g., 13C3- (m+3),
13C5- (m+5), and
13C6-citrate (m+6) (Figure 4).
These labeled species indicate that the production of labeled
acetyl-CoA and OAA isotopologues from the glutamine tracer
are using pathways external to the TCA cycle. Figure S2D
depicts the pathways that can lead to the synthesis of 13C3-,
13C5-, and
13C6-citrate. These include the cytoplasmic ATP-
citrate lyase (ACL) plus malic enzyme (ME) reactions, which
produce, respectively, 13C4/
13C2-OAA and
13C3/
13C2-pyruvate;
the latter yields 13C2/
13C1-acetyl-CoA via pyruvate dehydroge-
nase (PDH). Condensation of the labeled OAA and acetyl-CoA
species derived from the ACL-ME pathway, glycolysis, and the
TCA cycle produces 13C3 to
13C6-citrate (light blue circles, Fig-
ure S2D). In particular, the presence of the 13C6-citrate isotopo-Celllogue unambiguously confirmed the production of fully labeled
acetyl-CoA from the glutamine tracer via the ACL-ME-PDH
pathway. Labeled acetyl-CoA production from the ACL reaction
is further supported by 13C label incorporation into lipids such
as triacylglycerides (TAGs) and phosphatidylcholines (PCs)
(Figure S2E).
The 13C3- and
13C5-citrate isotopologues can also be formed
from the ACL-ME plus pyruvate carboxylase (PC) reactions
(green circles, Figure S2D). Pyruvate carboxylase is active in
P493 cells, as evidenced from the labeled glucose tracer exper-
iment described above (Figure 2). The operation of the ACL-
ME1-PDH and ACL-ME1-PC pathways is further corroborated
by the production of 13C3-succinate, -fumarate, and -malate,
which cannot be formed from labeled glutamine via the TCA
cycle activity alone. Finally, the production of 13C5-citrate from
the glutamine tracer can also be explained by reductive carbox-
ylation of aKG to form citrate (orange circles, Figure S2D),Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inc. 113
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Figure 3. MYC Induces Glutamine to Glutamate Conversion that Persists in Hypoxia
(A) Diagram of 13C labeling patterns products with 13C5,
15N2-Gln as tracer. Glutamine is labeled at all five carbon and both nitrogen atoms. Glutaminase (GLS)
activity produces glutamate 13C15N1 with the loss of the amido nitrogen as ammonia. Red and green circles, respective
13C and 15N labeling of glutamate from the
glutaminase reaction; light blue circles, 13C labeling of glutamate from the transamination of a-ketoglutarate; black, unlabeled N; GS, glutamine synthetase.
(B) 1-D 1H{13C} HSQC NMR spectra of cell extracts of P493 MYC ON versus MYC OFF. Intracellular 13C-4-glutamate production from glutamine was reduced
when MYC is off in aerobic condition. The conversion of glutamine to glutamate in hypoxia was as high as aerobic condition regardless of MYC expression. NMR
spectra were recorded at 800 MHz and 20C. Each 1H peak arose from protons directly attached to 13C, and the peak assignment denotes the 13C-carbon. The
peak intensity reflects 13C abundance of the attached carbon.
(C) Glutamine levels in the media. P493 cells were treated with 0.1 mg/ml tetracycline (MYC OFF) or without tetracycline (MYC ON) for 48 hr in hypoxic (H) or
aerobic (A) conditions and were grown in 13C5,
15N2-Gln (m+7) medium in the presence or absence of tetracycline for 24 hr. Media metabolites were analyzed by
GC-MS. Under aerobic conditions, glutamine consumption was decreased when MYC is off. Under hypoxia, glutamine consumption was decreased. The
metabolite concentration was expressed as mmole/g protein dry weight.
(D) GC-MS analysis of intracellular conversion of 13C5,
15N2-glutamine to glutamate. The m+5 glutamate was primarily
13C5-glutamate (cf. Figure S1E) with no
15N label, which is derived from 13C5-aKG via transamination. The data shown in (B)–(D) were performed three times. The error bars represent SEM.
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and IDH as recently reported in other cells (Metallo et al., 2011;
Mullen et al., 2011; Wise et al., 2011; Yoo et al., 2008) and driven
by the hydrolysis of ATP via citrate lyase and ACC. There is abun-
dant CO2/HCO3
 in cell culture for reductive carboxylation and
presumably in tissue from a number of decarboxylation reac-
tions. However, the relative proportion of the m+5 versus m+3,
m+4, and m+6 species, which are characteristic of the forward
reactions in the Krebs cycle plus pyruvate carboxylase activity,
indicates that reductive carboxylation is not the major pathway
in P493 cells, especially under aerobic conditions in which the
ratio of aKG to citrate concentration was very low (Figure 4);
a high ratio is important for driving this thermodynamically uphill
reaction.114 Cell Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier InWe were also intrigued by the apparent upregulation of such
TCA cycle-mediated glutamine metabolism by MYC and its
persistence under hypoxia (Figure 4). Such a glucose-indepen-
dent TCA cycle activity would be advantageous for cancer cells
subjected to glucose deficiency and/or hypoxia in the tumor
microenvironment. Thus, we next determined whether the gluta-
mine-mediated TCA cycle can operate in the absence of glucose
andwhether glutaminemetabolism alone can sustain cell growth
and survival.
P493 cells were grown in the absence of glucose using the
tracer [U-13C,15N]-Gln to determine whether TCA cycle interme-
diates could be derived solely from glutamine (Figure 5). In the
absence of glucose, the P493 cells completed one doubling in
3 days under aerobic conditions with MYC ON compared withc.
Figure 4. P493 Cells Were Grown in 13C5,
15N2-Glutamine Medium with Glucose
MYC induces glutamine entry into the TCA cycle, which persists in hypoxia. 13C5,
15N2 glutamine enters the Krebs cycle to produce a-ketoglutarate, succinate,
fumarate, and malate. Citrate can be generated by reductive carboxylation (RedCarb) of glutamine-derived a-ketoglutarate (m+5) (orange circles) or via the
forward reactions of the cycle. Malic enzyme (ME) catalyzes the oxidative decarboxylation of malate to pyruvate (light blue). This pyruvate pool (m+3) can be
a precursor for both m+2 acetyl-CoA and m+3 OAA (from pyruvate carboxylation, green circles) to make m+5 citrate. The citrate m+6 isotopologue could only
arise from glutamine-derived m+4 oxaloacetate (from forward cycle reactions, red circles) and m+2 acetyl-CoA (mediated by malic enzyme). The isotopologue
distributions were determined by GC-MS. Each value is an average of duplicate samples. The data shown were performed three times. GPT2, glutamate-
pyruvate transaminase; ME,malic enzyme; PC, pyruvate carboxylase; GLS, glutaminase; CO2 indicates where carbon dioxide is released. A, aerobic; H, hypoxic.
The error bars represent SEM.
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Glucose-Independent Glutamine-Dependent TCA Cycledoubling every 34 ± 2 hr in the presence of glucose (Fig-
ure S3A). The cells consumed glutamine (Figure S3B) to produce
13C5-aKG (m+5) in a MYC-dependent fashion (circled red, Fig-
ure 5). The continued functioning of the TCA cycle under
glucose-deprived conditions was identified by the production
of various isotopologues of fumarate, malate, and aspartate,
particularly the 13C4-isotopologues (m+4, Figure 5). However,
these labeled isotopologues accumulated to much higher levels
(>100-fold for 13C4-Asp) than under glucose-replete conditions
(compare Figures 4 and 5 or Figure 1B and Figure S3C). This
could result from a lower supply of acetyl-CoA under glucose-
deprived conditions such that excess glutamine-derived OAA
was transaminated to form aspartate. This is also consistent
with the lower levels of labeled citrate and aKG isotopologues
in glucose-deprived cells than those found in glucose-replete
cells (Figures 4 and 5). In the absence of glucose, it is also
notable that 13C incorporation from the glutamine tracer into all
TCA cycle intermediates decreased under hypoxia but increased
with MYC OFF (Figure 5). Furthermore, the 13C alanine isotopo-
logues (e.g., 13C3-Ala or m+3 in Figure 5) showed the oppositeCellbehavior in response to MYC expression, regardless of the O2
conditions. The significant buildup of labeled alanine was in
contrast to a small production of lactate from glutamine (Fig-
ure S3C), which again argues against the operation of the canon-
ical glutamine to lactate pathway in P493 cells.
The relatively low accumulation of labeled TCA metabolites
with MYC ON under glucose deprivation could be caused by
a combination of limited TCA cycling and the demands for cell
proliferation and cell maintenance. The same argument could
also apply to aerobic versus hypoxic conditions. In Figure S3A,
the highest proliferation rate was observed under aerobic con-
ditions with MYC ON, followed by MYC OFF under aerobic
conditions, whereas under hypoxia there was little proliferation
regardless of the MYC status. With a slowdown of TCA cycling
due to glucose deficiency, a higher consumption rate of labeled
TCA intermediates for cell proliferation could deplete these
metabolites for both MYC ON and MYC OFF, but more so for
MYC ON than MYC OFF and with more depletion under
aerobic than hypoxic conditions (Figure 5). Diversion of gluta-
mine for maintenance purposes, e.g., glutathione synthesis forMetabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inc. 115
Figure 5. Glutamine-Driven Glucose-Independent TCA Cycle
P493 cells were grown in 13C5,
15N2-glutamine medium without glucose. The isotopologue distributions were determined by GC-MS. Under glucose-deprived
conditions, the m+5 a-ketoglutarate from labeled glutamine was produced in a MYC-dependent fashion. Labeled glutamine was also incorporated into m+4
isotopologues of fumarate and malate downstream of a-ketoglutarate. These isotopologues decreased under hypoxia but not with decreased MYC. The m+3
alanine isotopologue, which is derived from the transamination of glutamine-derived m+3 pyruvate (via malic enzyme), was highly elevated under high MYC and
aerobic conditions. Each value is an average of duplicate samples. Colored circles denote the same sets of reactions as in Figure 4. GPT2, glutamate-pyruvate
transaminase; ME,malic enzyme; PC, pyruvate carboxylase; GLS, glutaminase; CO2 indicates where carbon dioxide is released. A, aerobic; H, hypoxic. The error
bars represent SEM.
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Glucose-Independent Glutamine-Dependent TCA CycleROS detoxification (inferred by increased ROS production with
BPTES inhibition of glutaminolysis, Figure S4A) could also lead
to less flux through the TCA cycle. This is consistent with a higher
buildup of glutamine-derived glutathione with aerobic and MYC
ON conditions (Figure S3C).
When TCA cycling is faster, as in glucose-replete cells, the
production rate for the labeled TCA intermediates may be higher
than their consumption rate, leading to a higher buildup of these
labeled metabolites when MYC is overexpressed (Figure 4). The
bottleneck in TCA cycling could also contribute to the significant
buildup of 13C3-Ala (m+3) alanine under MYC ON and glucose
deprivation (Figure 5) via excess production of glutamine-
derived pyruvate (by way of the ACL-ME1 pathway, Figure S4),
which is transaminated to form alanine via glutamic pyruvic
transaminase 1 or 2. Again, this did not occur under glucose-
replete conditions, in which glucose, not glutamine, was the
main source of alanine production (Figure 2). In the absence
of glucose and under hypoxia, P493 cells did not proliferate
but continued to consume glutamine and remained viable
(Figure S3A).
Under aerobic conditions with MYC ON, the percentages of
viable (78% versus 76%) and proliferating (R2, 30.6% versus116 Cell Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier In30.3%) cell populations were similar between glucose-replete
(Figure S6) and -deplete conditions (Figure S7). This can be
mediated by the ability of glutamine metabolism to alleviate
oxidative stress (Figure S4A) and to support cell bioenergetics
(Figure S4B). These data show that when driven by MYC, gluta-
mine plays a crucial role for both cell survival and proliferation
under glucose deprivation.
Thus, the above observations confirm a reprogrammed gluta-
mine-dependent TCA cycle that functions in the absence of
glucose. Figure S4C outlines the pathways bywhich 13C carbons
of glutamine are converted to labeled acetyl-CoA and reenter
the TCA cycle. The significant presence of 13C5- (m+5) and
13C6-citrate (m+6, Figure 5) is consistent with an ACL-ME-
mediated production of acetyl-CoA and citrate solely from gluta-
mine. The 13C labeling of lipid acyl chains, although at relatively
low levels (Figure S4D), and the increased labeling under aerobic
with MYC ON confirm the activity of ACL and are consistent with
the higher rate of proliferation under these conditions (Fig-
ure S3A). However, since there was a significant level of unla-
beled and 13C4-citrate (m+4, Figure 5) under glucose depriva-
tion, there must also be a source(s) of unlabeled acetyl-CoA
that contributes to the continued operation of the TCA cycle.c.
Figure 6. Glutamine Contributes to Glutathione Synthesis and Redox Homeostasis
(A) Diagram of glutaminemetabolism to glutathione. Glutamine, when converted to glutamate, is involved in the import of cystine through the antiporter SLC7A11.
Cystine is converted to cysteine for the synthesis of glutathione, which also requires glycine and glutamine-derived glutamate.
(B) 1-D 1H{13C} HSQCNMR analysis of 13C-reduced (*GSH) plus oxidized (*GSSG) glutathiones indicates that the fraction of glutamine contributing to glutathione
production was sustained under hypoxia (H) as compared to aerobic condition (A). 13C incorporation was estimated from the 13C-4 peak of the glutamate residue
in GSH+GSSG by 1D HSQC NMR.
(C) FT-ICR-MS determination of glutathione oxidation. The 13C5 and
13C10 isotopologues of GSSG were most likely derived from the
13C5,
15N2-glutamine tracer
via respective incorporation of one and two units of 13C5-Glu. The error bars in (B) and (C) represent SEM.
(D) Glutamine-dependent redox homeostasis. Flow cytometric histograms of ROS levels were determined by DCFDA fluorescence in P493 cells treated with
2, 10, and 20 mM BPTES for 24 and 48 hr.
(E) Mean fluorescence intensity (MFI). MFI for DCFDA fluorescence is shown for the different concentrations of BPTES under aerobic and hypoxic conditions.
MFI was determined from triplicate experiments with SD and p values (t test) shown.
Cell Metabolism
Glucose-Independent Glutamine-Dependent TCA CycleWehave observed that fatty acid oxidation, a possible source for
unlabeled acetyl-CoA, increased in the absence of ectopic MYC
in P493 cells (Figure S5B). This could account for the higher
levels of 13C4-citrate when MYC was off (Figure 5). However, it
cannot explain the comparable levels of unlabeled citrate (m+0
Figure 5) between aerobic MYC ON and MYC OFF. Therefore
other sources of unlabeled acetyl CoA, such as oxidation of
amino acids, may also exist.
Glutamine-Dependent Bioenergetics and Redox
Homeostasis, a Cell Survival Pathway in Hypoxia
The dependence of P493 cells on glutamine for proliferation and
maintenance under aerobic and hypoxic conditions suggests
a key role for glutamine in driving anaplerotic and bioenergetic
needs of both dividing and resting cells. We found that the inter-
ruption of glutamine metabolism with the glutaminase inhibitorCellBPTES decreased ATP levels under aerobic conditions. In
hypoxia, cells maintained a lower ATP level that was further
diminished by BPTES treatment (Figure 7B). These results
suggest that glutamine metabolism via the glucose-independent
TCA cycle supports cellular bioenergetics for cell survival (and
proliferation) under both aerobic and hypoxic conditions.
In addition, both dividing and resting cells require redox
homeostasis, not only for continuing glycolysis but also for
detoxifying ROS. Glutamine, when converted to glutamate,
could also be involved in the import of cystine through the anti-
porter SLC7A11 (Figure 6A). This is consistent with the sig-
nificant excretion of labeled glutamate into the culture medium
(Figure 3C). Cystine, when converted to cysteine, contributes
to the synthesis of glutathione together with glycine and gluta-
mate derived from glutamine. We thus determined the con-
tributions of labeled glutamine and glucose to total de novoMetabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inc. 117
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Figure 7. Effects of a Glutaminase Inhibitor on Neoplastic Cells In Vitro and in a Tumor Xenograft Model In Vivo
(A) Effect of glutaminase inhibitor, BPTES, on aerobic and hypoxic P493 cell growth. Growth of control cells compared with cells treated with BPTES under both
aerobic and hypoxic conditions. All cells were grown at 1 3 105 cells/mL. Cell counts were performed in triplicate and shown as mean ±SD. Live cells were
counted daily in a hemocytometer using trypan blue dye exclusion.
(B) Effect of BPTES on steady-state ATP levels. P493 cells were treated with 2 mMBPTES for 20 hr and counted. ATP levels (mean ±SD, n = 3 experiments) were
determined by luciferin-luciferase-based assay on aliquots containing an equal number of live cells. *p = 0.0006; **p = 0.01 (t test).
(C) Effects of hypoxia and glucose deprivation on oxygen consumption rates. Oxygen consumption rates of aerobic (A) or hypoxic (H) P493 cells were determined
by a Clark-type oxygen electrode after culture in the presence or absence of glucose for 24 hr. Data are from duplicate experiments with SD and p values (t test)
shown.
(D) In vivo efficacy of BPTES. 2.0 3 107 P493 human lymphoma B cells were injected subcutaneously into tumor-bearing SCID mice. When the tumor volume
reached 100 mm3, 200 mg BPTES was injected every other day by intraperitoneal (i.p.) administration (12.5 mg/kg bodyweight) for 20 days. Control animals were
treated with daily i.p. injection of vehicle (2% [vol/vol] DMSO). BPTES inhibited lymphoma xenograft growth as compared to control. The tumor volumes were
measured using digital calipers every 4 days and calculated using the following formula: (length [mm]3 width [mm]3 width [mm]3 0.52). The results represent
the average ±SEM (n = 7 each).
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Glucose-Independent Glutamine-Dependent TCA Cycleglutathione synthesis by quantifying 13C-labeled reduced plus
oxidized glutathione levels derived from respective glucose or
glutamine tracers (Figure 6B; *GSH-*GSSG). Relative to glucose,
glutamine carbonsweremore readily incorporated into the gluta-
mate moiety of the glutathione, indicating that glutamine, not
glucose, is the main precursor for glutathione synthesis. While
the glucose carbon contribution to glutathione diminished in
hypoxia, the contribution from glutamine carbons persisted.
Furthermore, the 13C fractional distribution in oxidized gluta-
thione (GSSG) isotopologues (e.g., m+5 and m+10 in Figure 6C)
was in fact higher under hypoxia with MYC ON than under
aerobic with MYC OFF, which could reflect a higher ROS pro-
duction or oxidation of de novo-synthesized glutathione in
response to MYC expression and hypoxia. This observation is
supported by a lower level of reduced glutathione (GSH) (Fig-
ure S5D) and higher ROS production (Figure 6D) in P493 cells
under hypoxia and inhibition of glutaminase by BPTES. The
order of GSH levels was aerobic control > hypoxic control >
aerobic BPTES > > hypoxic BPTES, while that of ROS produc-
tion (measured by DCFDA fluorescence) was reversed, which
is expected for removal of ROS by oxidation of GSH to GSSG.
To determine further the role of glutaminase in redox homeo-
stasis, we isolated T cells from mice that are heterozygous for118 Cell Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inmitochondrial glutaminase 1 (Gls+/) (Masson et al., 2006), which
is the homolog of human kidney type glutaminase rather than
liver-specific glutaminase 2. When compared to aerobic and
hypoxic wild-type (WT) T cells, theGls+/ T cells had higher basal
ROS levels, which were further increased under hypoxia (Fig-
ure S5E). Altogether, these data suggest that MYC expression
can enhance aerobic glutathione biosynthesis from glutamine
to maintain redox homeostasis. Glutamine-derived glutathione
production was also sustained under hypoxia to cope with
heightened ROS production from the perturbed mitochondrial
electron transport chain (Chandel et al., 1998; Guzy et al., 2005).
Our findings that MYC-induced glutamine metabolism per-
sisted in hypoxia and in the absence of glucose for cell mainte-
nance led us to test whether targeting glutaminase is feasible
for cancer therapy. We determined the consequences of BPTES
treatment on aerobic and hypoxic P493 cell proliferation (Fig-
ure 7A). While BPTES decreased glutaminase activity (Fig-
ure S5C) and the proliferation of aerobic P493 cells, inhibition
of glutaminase killed hypoxic P493 cells (Figure 7A). Under
hypoxia, the cells proliferated less but continued to import and
metabolize glutamine (Figure S2C and Figure 4) as well as
survive (Figure S6), even under glucose-deprived conditions
(Figure S7). The killing effect of BPTES under hypoxia can bec.
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Glucose-Independent Glutamine-Dependent TCA Cycleascribed to the crucial role of glutamine metabolism for survival
by supporting cell bioenergetics (Figure 7B) and alleviating
oxidative stress (Figure 6). This notion is consistent with the
persistent, although diminished, rate of oxygen consumption
by hypoxic cells as compared with aerobic cells (Figure 7C).
Glucose deprivation increases the rate of oxygen consumption
(Figure 7C) as previously reported (Gao et al., 2009). To deter-
mine the in vivo significance of our findings, P493 tumor xeno-
graft-bearing mice were treated with intraperitoneal injections
of BPTES (Figure 7D). As compared with DMSO vehicle-treated
mice, the BPTES-treated mice demonstrated a significantly
diminished tumor progression.
DISCUSSION
Although increased glucose metabolism has been hypothesized
to drive the bioenergetic needs of cancer cells, it is clear that
highly proliferative cancer cells require additional supplies of
biosynthetic precursors not met by glucose metabolism; thus
there is the requirement of anaplerosis via glutaminolysis and/
or pyruvate carboxylation as well as other sources such as fatty
acids (DeBerardinis et al., 2007; Deberardinis et al., 2008; Fan
et al., 2009; Gao et al., 2009; Wise et al., 2008). A significant
proportion of the biosynthetic needs under aerobic conditions
may be met by glutamine metabolism, which is regulated by
the activity of the MYC oncogene (Gao et al., 2009; Wise et al.,
2008). In this regard, our previous studies documented the ability
of MYC to induce mitochondrial biogenesis, function, and
enhanced oxygen consumption (Li et al., 2005), which persisted
under hypoxia (Figure 7C). Our data show that the import rates
of both glucose and glutamine greatly exceed those of other
amino acids under these various experimental conditions, sug-
gesting that they are the major sources for energy and anaplero-
sis. However, it is a long-standing question how cancer cells
survive or even proliferate under the hypoxic and nutrient-
deprived conditions encountered in the tumor microenvironment
(Schroeder et al., 2005).
Solid tumors are often poorly vascularized, leading to regions
of hypoxia and glucose deficiency (Goel et al., 2011; Schroeder
et al., 2005), which must be overcome for cancer cells to con-
tinue proliferation and survive. Although MYC-overexpressing
cells appear to become addicted to glutamine, the heightened
addiction to glutamine under hypoxia had not been previously
established (Yuneva et al., 2007). We therefore determined
how limited oxygen availability would influence glutamine
metabolism in vitro to gain insights into what might happen
in vivo. It should be noted, however, that our well-controlled
cell line studied in vitro may have adapted epigenetically and
metabolically to prolonged cultures in nutrient-rich conditions,
and hence metabolic changes under our in vitro experimental
conditions may be instructive, but may not fully represent what
happens in vivo in the tumor microenvironment. Notwithstanding
this caveat, we used uniformly labeled [U-13C,15N]-Gln and
traced the fate of glutamine carbon and nitrogen atoms in both
aerobic and hypoxic conditions with MYC turned OFF or ON in
a human B cell model of Burkitt lymphoma (P493). The P493
system is strictly dependent on MYC function for cell pro-
liferation; as such, this experimental model does not conclu-
sively allow us to distinguish the metabolic consequences ofCellMYC-mediated transcriptional changes versus those that occur
due to changes in cell size increase or proliferative status as
previously reported (Schuhmacher et al., 1999). We surmise
that most of the metabolic changes between MYC ON and
MYC OFF states are consequential to MYC regulation of genes
involved in both glucose and glutamine metabolism as previ-
ously documented (Dang et al., 2009a). The entry of glutamine,
after its conversion to glutamate and then to a-ketoglutarate,
into the TCA and oxidation to succinate, fumarate, and malate
were highly facilitated by MYC expression. More intriguingly,
glutaminemetabolism via the TCA cycle persisted under hypoxia
and remained responsive toMYC. Based on detailed analyses of
13C isotopologues of citrate, succinate, fumarate, and malate
(Figure 4), we uncovered a glucose-independent TCA cycle
solely supported by glutamine, which involved the supply of
acetyl-CoA and OAA to the TCA cycle by the combined activity
of ATP citrate lyase, ME, PDH, and/or pyruvate carboxylase (Fig-
ure 4). This pathway was operative even when glucose was
abundant and remained active under hypoxia. These data col-
lectively define a more efficient pathway of glutaminolysis, in
which glutamine can be used either for anabolic purposes for
proliferation, or for producing energy. This pathway can produce
up to 17.5 mol ATP/mol glutamine oxidized to CO2. This is in
contrast to the canonical glutaminolysis pathway from glutamine
to lactate (Helmlinger et al., 2002; Newsholme et al., 1985a,
1985b), in which the glutamine carbons are not oxidized via the
TCA cycle and produce only 5 ATP/mol glutamine converted to
lactate + CO2.
To further explore the role of the glucose-independent TCA
cycle, we traced glutamine metabolism under glucose-deprived
culture conditions. SIRM analysis of TCA cycle metabolites re-
vealed a relative increase in this glutamine-mediated pathway
in glucose-deprived conditions, as evidenced by the increase
in the ratios of 13C6-citrate and
13C5-citrate to
13C4-citrate (Fig-
ure 5). The metabolites produced through this glutamine path-
way provided the anabolic precursors (citrate) for lipid synthesis
(Figure S4D) and cell survival precursor (Glu) for glutathione
production (Figure 6B, Figure S3C), which was commensurate
with the aerobic growth demand (Figure S3A) and the need for
ROS quenching under hypoxia (Figure 6). These observations
are consistent with our previous findings that knockdown of
glutaminase by siRNA resulted in increased ROS and slowed
growth that could be partially rescued by N-acetylcysteine
(Gao et al., 2009). It is also notable that pyruvate carboxylase
plays a significant role in this glutamine pathway (Figures 4
and 5) and that glutamine-independent tumor cells use pyruvate
carboxylase to drive a glucose-dependent TCA cycle in the
absence of glutamine (Cheng et al., 2011). Thus, the flexibility
of the TCA cycle to use either or both anaplerotic pathways
may be important for tumor adaptation. More practically, thera-
peutic approaches targeting metabolism must consider these
adaptive strategies.
As a proof of concept, we tested the effect of a glutaminase
inhibitor (BPTES) on growth and ROS production of P493 cells
and showed that blocking glutamine metabolism not only in-
hibited tumor cell growth under aerobic conditions but also led
to cell death under hypoxia and reduction of tumor xenograft
growth in vivo (Figures 7A and 7D). The specificity of BPTES
was previously documented by our studies in glioma cells, whichMetabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inc. 119
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Glucose-Independent Glutamine-Dependent TCA Cyclerevealed BPTES-induced metabolic changes, such as dimin-
ished glutamate, a-ketoglutarate, succinate, fumarate, and
malate levels, consistent with an on-target effect on glutaminase
(Seltzer et al., 2010). Further, the uncompetitive nature of BPTES
inhibitory activity was recently underscored by the crystal struc-
ture of glutaminase (GAC form) cocrystallized with BPTES, which
sits at the oligomerization interface of the glutaminase tetramer
(Delabarre et al., 2011). Our finding of a glutamine-driven TCA
cycle and other recent discoveries of cancer-related metabolic
pathways (Dang et al., 2009b; Frezza et al., 2011; Possemato
et al., 2011) suggest that metabolic flexibility may be a common
feature of tumor cell metabolism. Hence, a broader and deeper
understanding of cancer cell metabolism and their ability to
reprogram canonical biochemical pathways under metabolic
stress can be a rich ground for uncovering strategies for thera-
peutic targeting of tumors.
EXPERIMENTAL PROCEDURES
Detailed materials and methods are available online in the Supplemental
Information.
13C-Labeled Glutamine or Glucose and Hypoxic Exposure
Briefly, Human lymphoma B P493 cells were grown in [U-13C]-labeled glucose
or [U-13C,15N]-labeled glutamine for 24 hr. Nonhypoxic cells (21% [(vol/vol] O2)
were maintained at 37C in a 5% (vol/vol) CO2 and 95% (vol/vol) air incubator.
Hypoxic cells (1% O2) were maintained in a controlled atmosphere chamber
(PLAS-LABS) with a gas mixture containing 1% O2, 5% (vol/vol) CO2, and
94% (vol/vol) N2 at 37
C for 48 hr. Metabolites were extracted from cells
and media as previously described (Fan et al., 2011).
Bromobimane and carboxy-H2DCFDA were used to measure reduced
glutathione ROS levels, respectively, using flow cytometry.
ATP Levels
ATP levels were determined by luciferin-luciferase-based assay (Promega).
Glutaminase Activity
Cells treated with BPTES and/or tetracycline were then incubated with [3H]
glutamine to assess glutaminase activity.
The b-oxidation of 14C labeled oleic acid was used to assess fatty acid
oxidation.
Cell Viability Assay
The presence of dead cells was determined by propidium iodide staining at
2 mg/ml using flow cytometry.
Statistical Analysis
Values are shown as mean ± standard deviation (SD) or standard error of the
mean (SEM). Data were analyzed using the Student’s t test, and significance
was defined as p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2011.12.009.
ACKNOWLEDGMENTS
This work was supported by in part by grant 1R21NS074151-01 (to T.T.);
The Sol Goldman Pancreatic Cancer Research fund (to A.L.); grants
5R01CA051497-21 and 5R01CA057341-20, Leukemia Lymphoma Society
grant LLS-6363-11, and Stand-Up-to-Cancer/American Association for
Cancer Research translational grant (to C.V.D.); grants 1R01CA118434-01A2
and 3R01CA118434-02S1, University of Louisville CTSPGP grants 20044120 Cell Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier In(to T.W.M.F.) and 20061 (to A.N.L.); and National Institutes of Health National
Center for Research Resources (NIH NCRR) grant 5P20RR018733, Kentucky
Challenge for Excellence, the Brown Foundation, and Kentucky Lung Cancer
Research Program (postdoctoral fellowship to P.K.L.). The FT-ICR-MS instru-
mentation was supported by the National Science Foundation’s Office of
Experimental Program to Stimulate Competitive Research (NSF/EPSCoR)
grant number EPS-0447479. We thank Ramani Dinavahi, Julie Tan, and
Radhika Burra for excellent technical assistance and Stephen Rayport for the
heterozygous glutaminase mice. A.L., A.N.L., T.W.M.F., and C.V.D. designed
research and wrote the manuscript. A.L., A.N.L., M.H., S.B., J.B., C.J.R.,
H.Z., L.J.Z., R.J.C.S., P.K.L., R.M.H., and T.W.M.F. performed research; all
authors interpreted the data and commented on the manuscript.
Received: November 3, 2011
Revised: December 8, 2011
Accepted: December 14, 2011
Published online: January 3, 2012
REFERENCES
Bensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N., Nakano, K., Bartrons, R.,
Gottlieb, E., and Vousden, K.H. (2006). TIGAR, a p53-inducible regulator of
glycolysis and apoptosis. Cell 126, 107–120.
Chandel, N.S., Maltepe, E., Goldwasser, E., Mathieu, C.E., Simon, M.C., and
Schumacker, P.T. (1998). Mitochondrial reactive oxygen species trigger
hypoxia-induced transcription. Proc. Natl. Acad. Sci. USA 95, 11715–11720.
Cheng, T., Sudderth, J., Yang, C., Mullen, A.R., Jin, E.S., Mates, J.M., and
DeBerardinis, R.J. (2011). Pyruvate carboxylase is required for glutamine-
independent growth of tumor cells. Proc. Natl. Acad. Sci. USA 108, 8674–
8679.
Dang, C.V. (2010). Rethinking the Warburg effect with Myc micromanaging
glutamine metabolism. Cancer Res. 70, 859–862.
Dang, C.V., Le, A., and Gao, P. (2009a). MYC-induced cancer cell energy
metabolism and therapeutic opportunities. Clin. Cancer Res. 15, 6479–6483.
Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M.,
Fantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2009b). Cancer-associ-
ated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744.
Dang, L., Jin, S., and Su, S.M. (2010). IDH mutations in glioma and acute
myeloid leukemia. Trends Mol. Med. 16, 387–397.
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S.,
and Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can
engage in glutamine metabolism that exceeds the requirement for protein and
nucleotide synthesis. Proc. Natl. Acad. Sci. USA 104, 19345–19350.
Deberardinis, R.J., Sayed, N., Ditsworth, D., and Thompson, C.B. (2008). Brick
by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54–61.
Delabarre, B., Gross, S., Fang, C., Gao, Y., Jha, A., Jiang, F., Song, J.J., Wei,
W., and Hurov, J.B. (2011). Full-length human glutaminase in complex with an
allosteric inhibitor. Biochemistry 50, 10764–10770.
Fan, T.W., Lane, A.N., Higashi, R.M., Farag, M.A., Gao, H., Bousamra, M., and
Miller, D.M. (2009). Altered regulation of metabolic pathways in human lung
cancer discerned by 13C stable isotope-resolved metabolomics (SIRM).
Mol. Cancer 8, 41.
Fan, T.W.-M., Yuan, P., Lane, A.N., Higashi, R.M., Wang, Y., Hamidi, A., Zhou,
R., Guitart-Navarro, X., Chen, G., Manji, H.K., et al. (2010). Stable isotope
resolved metabolomic analysis of lithium effects on glial-neuronal interactions.
Metabolomics 6, 165–179.
Fan, T.W.-M., Lane, A.N., Higashi, R.M., and Yan, J. (2011). Stable isotope
resolved metabolomics of lung cancer in a scid mouse model. Metabolomics
7, 257–269.
Frezza, C., Zheng, L., Folger, O., Rajagopalan, K.N., MacKenzie, E.D., Jerby,
L., Micaroni, M., Chaneton, B., Adam, J., Hedley, A., et al. (2011). Haem oxy-
genase is synthetically lethal with the tumour suppressor fumarate hydratase.
Nature. 10.1038/nature10363.
Gao, P., Tchernyshyov, I., Chang, T.C., Lee, Y.S., Kita, K., Ochi, T., Zeller, K.I.,
De Marzo, A.M., Van Eyk, J.E., Mendell, J.T., et al. (2009). c-Myc suppressionc.
Cell Metabolism
Glucose-Independent Glutamine-Dependent TCA Cycleof miR-23a/b enhances mitochondrial glutaminase expression and glutamine
metabolism. Nature 458, 762–765.
Goel, S., Duda, D.G., Xu, L., Munn, L.L., Boucher, Y., Fukumura, D., and Jain,
R.K. (2011). Normalization of the vasculature for treatment of cancer and other
diseases. Physiol. Rev. 91, 1071–1121.
Guzy, R.D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K.D., Simon,
M.C., Hammerling, U., and Schumacker, P.T. (2005). Mitochondrial complex
III is required for hypoxia-induced ROS production and cellular oxygen
sensing. Cell Metab. 1, 401–408.
Helmlinger, G., Sckell, A., Dellian, M., Forbes, N.S., and Jain, R.K. (2002). Acid
production in glycolysis-impaired tumors provides new insights into tumor
metabolism. Clin. Cancer Res. 8, 1284–1291.
Kim, J.W., Tchernyshyov, I., Semenza, G.L., and Dang, C.V. (2006). HIF-1-
mediated expression of pyruvate dehydrogenase kinase: a metabolic switch
required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185.
Kim, J.W., Gao, P., Liu, Y.C., Semenza, G.L., and Dang, C.V. (2007). Hypoxia-
inducible factor 1 and dysregulated c-Myc cooperatively induce vascular
endothelial growth factor and metabolic switches hexokinase 2 and pyruvate
dehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381–7393.
Kim, J., Lee, J.H., and Iyer, V.R. (2008). Global identification of Myc target
genes reveals its direct role in mitochondrial biogenesis and its E-box usage
in vivo. PLoS One 3, e1798. 10.1371/journal.pone.0001798.
King, A., Selak, M.A., and Gottlieb, E. (2006). Succinate dehydrogenase and
fumarate hydratase: linking mitochondrial dysfunction and cancer.
Oncogene 25, 4675–4682.
Koppenol, W.H., Bounds, P.L., and Dang, C.V. (2011). Otto Warburg’s contri-
butions to current concepts of cancer metabolism. Nat. Rev. Cancer 11,
325–337.
Li, F., Wang, Y., Zeller, K.I., Potter, J.J., Wonsey, D.R., O’Donnell, K.A., Kim,
J.W., Yustein, J.T., Lee, L.A., and Dang, C.V. (2005). Myc stimulates nuclearly
encoded mitochondrial genes and mitochondrial biogenesis. Mol. Cell. Biol.
25, 6225–6234.
Masson, J., Darmon, M., Conjard, A., Chuhma, N., Ropert, N., Thoby-Brisson,
M., Foutz, A.S., Parrot, S., Miller, G.M., Jorisch, R., et al. (2006). Mice lacking
brain/kidney phosphate-activated glutaminase have impaired glutamatergic
synaptic transmission, altered breathing, disorganized goal-directed behavior
and die shortly after birth. J. Neurosci. 26, 4660–4671.
Metallo, C.M., Gameiro, P.A., Bell, E.L., Mattaini, K.R., Yang, J., Hiller, K.,
Jewell, C.M., Johnson, Z.R., Irvine, D.J., Guarente, L., et al. (2011).
Reductive glutamine metabolism by IDH1 mediates lipogenesis under
hypoxia. Nature. Published online November 20, 2011. 10.1038/nature10602.
Mullen, A.R., Wheaton, W.W., Jin, E.S., Chen, P.H., Sullivan, L.B., Cheng, T.,
Yang, Y., Linehan, W.M., Chandel, N.S., and Deberardinis, R.J. (2011).
Reductive carboxylation supports growth in tumour cells with defective mito-
chondria. Nature. Published online November 20, 2011. 10.1038/nature10642.
Newsholme, E.A., Crabtree, B., and Ardawi, M.S. (1985a). Glutamine metabo-
lism in lymphocytes: its biochemical, physiological and clinical importance.
Q. J. Exp. Physiol. 70, 473–489.
Newsholme, E.A., Crabtree, B., and Ardawi, M.S. (1985b). The role of high
rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci.
Rep. 5, 393–400.
Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K.,
Sethumadhavan, S., Woo, H.-K., Jang, H.G., Jha, A.K., et al. (2011).CellFunctional genomics reveal that the serine synthesis pathway is essential in
breast cancer. Nature 476, 345–350.
Robinson, M.M., McBryant, S.J., Tsukamoto, T., Rojas, C., Ferraris, D.V.,
Hamilton, S.K., Hansen, J.C., and Curthoys, N.P. (2007). Novel mechanism
of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-
1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem. J. 406, 407–414.
Samudio, I., Fiegl, M., and Andreeff, M. (2009). Mitochondrial uncoupling and
the Warburg effect: molecular basis for the reprogramming of cancer cell
metabolism. Cancer Res. 69, 2163–2166.
Schroeder, T., Yuan, H., Viglianti, B.L., Peltz, C., Asopa, S., Vujaskovic, Z., and
Dewhirst, M.W. (2005). Spatial heterogeneity and oxygen dependence of
glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat.
Cancer Res. 65, 5163–5171.
Schuhmacher, M., Staege, M.S., Pajic, A., Polack, A., Weidle, U.H.,
Bornkamm, G.W., Eick, D., and Kohlhuber, F. (1999). Control of cell growth
by c-Myc in the absence of cell division. Curr. Biol. 9, 1255–1258.
Seltzer, M.J., Bennett, B.D., Joshi, A.D., Gao, P., Thomas, A.G., Ferraris, D.V.,
Tsukamoto, T., Rojas, C.J., Slusher, B.S., Rabinowitz, J.D., et al. (2010).
Inhibition of glutaminase preferentially slows growth of glioma cells with
mutant IDH1. Cancer Res. 70, 8981–8987.
Telang, S., Lane, A.N., Nelson, K.K., Arumugam, S., and Chesney, J.A. (2007).
The oncoprotein H-RasV12 increases mitochondrial metabolism. Mol. Cancer
6, 77.
Vander Heiden, M.G. (2011). Targeting cancer metabolism: a therapeutic
window opens. Nat. Rev. Drug Discov. 10, 671–684.
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009).
Understanding the Warburg effect: the metabolic requirements of cell prolifer-
ation. Science 324, 1029–1033.
Warburg, O. (1956). On the origin of cancer cells. Science 123, 309–314.
Warburg, O., Posener, K., and Negelein, E. (1924). Ueber den Stoffwechsel der
Tumoren. Biochem. Z. 152, 319–344.
Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, X.Y., Pfeiffer,
H.K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S.B., et al. (2008). Myc
regulates a transcriptional program that stimulates mitochondrial glutaminoly-
sis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105, 18782–
18787.
Wise, D.R., Ward, P.S., Shay, J.E., Cross, J.R., Gruber, J.J., Sachdeva, U.M.,
Platt, J.M., Dematteo, R.G., Simon, M.C., and Thompson, C.B. (2011).
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of
alpha-ketoglutarate to citrate to support cell growth and viability. Proc. Natl.
Acad. Sci. USA 108, 19611–19616.
Wu, W., Platoshyn, O., Firth, A.L., and Yuan, J.X. (2007). Hypoxia divergently
regulates production of reactive oxygen species in human pulmonary and
coronary artery smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol.
293, L952–L959.
Yoo, H., Antoniewicz, M.R., Stephanopoulos, G., and Kelleher, J.K. (2008).
Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipo-
cyte cell line. J. Biol. Chem. 283, 20621–20627.
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., and Lazebnik, Y.
(2007). Deficiency in glutamine but not glucose induces MYC-dependent
apoptosis in human cells. J. Cell Biol. 178, 93–105.Metabolism 15, 110–121, January 4, 2012 ª2012 Elsevier Inc. 121
